高级检索
当前位置: 首页 > 详情页

TRAIL inhibits platelet-induced colorectal cancer cell invasion

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Surgery, Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang, PR China [2]Department of Biochemistry and Molecular Biology, College of Basic Medicine, Key Laboratory of Medical Biotechnology of Hebei Province, Hebei Medical University, Shijiazhuang, PR China
出处:
ISSN:

关键词: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) platelet colorectal cancer CD62P metastasis transforming growth factor-beta 1

摘要:
Objective Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic ligand that activates the extrinsic apoptosis pathway of cell death receptors. This study aimed to evaluate the relationship between TRAIL and platelet-induced tumor metastasis in colorectal cancer. Methods Platelet P-selectin (CD62P) was measured by immunohistochemistry in tumor and adjacent normal tissues from 90 patients with colorectal cancer undergoing resection. Tumor cell invasion was assessed by transwell assay in the presence of platelets with or without TRAIL. The expression of TRAIL receptors DR4 and DR5 on platelets was assessed by flow cytometry, real-time polymerase chain reaction, and western blotting. Results P-selectin (CD62P) expression was significantly increased in tumor tissues compared with adjacent normal tissues. High CD62P expression was significantly correlated with tumor stage and vascular invasion. Tumor cell migration was increased by coculture with platelets, but this effect was inhibited by TRAIL. Transforming growth factor (TGF)-beta 1 secretion was significantly reduced in TRAIL-treated platelets. The TRAIL receptor DR5 but not DR4 was expressed in platelets according to flow cytometry. Conclusions TRAIL could inhibit metastasis and colon cancer cell invasion by promoting platelet apoptosis and reducing the release of TGF-beta 1.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
JCR分区:
出版当年[2019]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL Q4 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Department of Surgery, Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang, PR China
通讯作者:
通讯机构: [1]Department of Surgery, Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang, PR China [*1]Department of Surgery, Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang 050017, PR China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号